131I-Lipiodol (131I-Ethiodized Oil) is a generic therapeutic agent which was authorized and available since 1995 under the name Lipiocis® but withdrawn in October 2010 following the observation of lung toxicity. The product came back on the Indian market in 2018 (approval in India, March 2017). The precursor Lipiodol is a mixture of iodinated ethyl esters of fatty acids of poppy seed oil used as a contrast agent for radiology. When labeled with 131I it is used for the treatment of hepatocarcinoma (HCC) with portal vein thrombosis, non-resectable and untransplantable. 131I-Lipiodol is also available in Brazil.

Target/Mechanism: Fatty acid containing tissues

Leading Emitter: beta electrons (β–)